Advance Pharmaceutical to invest $25 million in building plant in Russia

13 September 2013

USA-based privately-held drugmaker Advance Pharmaceutical Inc is considering establishing a facility for the production of its drugs in Russia’s Belgorod region (Central Russia), according to the company.

Advance Pharmaceutical engages in the design, research and development, manufacture, marketing and distribution of prescription and over the counter pharmaceutical products.

Currently the company is continuing talks with the authorities of the Belgorod region, regarding details of the project. It is planned that the design capacity of the new plant will be up to 1,045 billion drug units. Estimated investment at the initial stage is 700 million roubles (around $25 million).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK